You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.
Natera and Qiagen have signed a 10-year agreement to develop cell-free DNA assays for use on Qiagen's GeneReader next-generation sequencing system.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
The project relates to an NGS-based clinical trial assay associated with a sponsored project agreement between Qiagen and an undisclosed pharmaceutical company.
The companies are aiming to develop Idylla-based CDx biomarker tests for a compound Amgen is developing to treat solid tumors.
The partners aim to develop jointly-branded clinical decision support software for faster, more accurate, and more confident decision-making.
Chembio said that under the agreement it will develop a quantitative, reader-based POC test that detects an undisclosed biomarker, and apply for FDA clearance.
The agreement could lead to a companion diagnostic that supports the development of an Inotrem compound in clinical trials for septic-shock treatment.